BioSpace News Archive

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 20th Annual Global Healthcare Conference at 10:35 a.m. Eastern Time on Tuesday, September 13, 2022 in New York. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.

Blueprint Medicines Corporation announced that, effective September 1, 2022, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 18,170 shares of its common stock and an aggregate of 9,083 restricted stock units to thirteen new employees under Blueprint Medicines’ 2020 Inducement Plan.

Virax Biolabs Group Limited announced that Virax’s Chairman of the Board of Directors and Chief Executive Officer, Mr. James Foster will present at H.C. Wainwright’s 24th Annual Global Investment Conference, held from September 12-14, 2022, in New York, NY.

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate virtually in a corporate presentation at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12th at 7:00am EST.

CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference at 5:15 p.m. ET on Tuesday, September 13, 2022.

Sientra, Inc., a medical aesthetics company uniquely focused on plastic surgeons, announced that on August 29, 2022, the Company approved equity award grants under the Sientra Inc. Inducement Plan to 49 new employees.

Centene Corporation announced it will present at the Morgan Stanley 20th Annual Global Healthcare Conference, to be held Monday, September 12th – Wednesday, September 14th in New York City.

QOL Medical, LLC, a ground-breaking, rare disease pharmaceutical company, announced today that the United States (U.S.) Food & Drug Administration (FDA) approved Sucraid® single-use containers for patients more than 33 lb (15 kg) with Congenital Sucrase-Isomaltase Deficiency (CSID).

Researchers have identified an immune biomarker in newborns that can predict the subsequent onset and severity of paediatric atopic eczema, a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress has shown.

atai Life Sciences N.V., a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor conferences in September.